Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

L'effetto dell'apprendimento precedente sul trattamento degli errori del morfema

13 luglio 2026 aggiornato da: University of Arizona

This is a small-scale treatment study designed to determine which teaching methods result in the best learning. Treatment focuses on helping children with a developmental language disorder learn parts of grammar. Preschool children will receive assessments to determine whether they have a developmental language disorder and what parts of grammar they have not mastered. Children will receive one-on-one behavioral treatment over a six week period. Half of the children will be first taught a grammatical form they sometimes use and then one they rarely use. The other half will only be treated for a grammatical form they rarely use. The study seeks to determine whether starting with something children sometimes use correctly (an easier part of speech) will speed later learning of something that is harder for them. The children's ability to use the grammatical forms taught to them will be assessed throughout the treatment period and approximately six weeks after treatment ends.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This is a early-efficacy treatment study designed to determine whether learning of a very low-use grammatical form can be made more efficient by beginning treatment with a form that is partially, but not fully acquired. Children qualify for the study by showing evidence of impaired language skills in the absence of intellectual disability, hearing loss, or other parent-reported handicapping conditions that could affect language skills. Preschool children with a developmental language disorder are provided 24 teaching episodes of Enhanced Conversational Recast daily for up to 25 days. Treatment gains are measured as change from baseline use of probes designed to measure generalization to untreated grammatical forms.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

35

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Arizona
      • Tucson, Arizona, Stati Uniti, 85721
        • University of Arizona

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 4 anni a 6 anni (Bambino)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Native English speaking
  • Passed a pure-tone hearing screening
  • 4-6 years of age
  • Structured Photographic Expressive Language Test-Preschool 2 (language) test score of < 87
  • Kaufman Assessment Battery for Children-II Nonverbal Scale (cognition) test score of >75
  • Sufficient morpheme errors to serve as treatment and control targets
  • Articulations skills sufficient to judge use of language targets
  • Able to attend treatment daily

Exclusion Criteria:

  • Parent report of other handicapping conditions
  • Clinical signs of other disorders
  • Enrolled in outside treatment

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Easy first

Children are treated for an emergent grammatical form that is used correctly at least 60% during three pre-treatment probe sessions. This form is treated until children generalize it's use an average of 90% or more across 3 probe sessions. Their treatment target is then switched to a grammatical form that is used less than 30% correct across 3 pre-treatment probe sessions.

The treatment procedure uses 24 treatment doses embedded into child-friendly activities (crafts, book reading, play). Each each consists of a clinician eliciting use of a targeted grammatical form, a child's attempt (correct or incorrect) to use that form, and an immediate clinician repetition of the child's attempt (a recast), correcting any ungrammatical elements as needed. Clinicians must also attempt to gain the child's attention before providing the recast. Treatment sessions are approximately 30 minutes in duration.

Comparatore attivo: Hard Only

Children are treated for a grammatical form that is used accurately less than 30% of the time during 3 pre-treatment probe sessions. This form is treated for the entire treatment period

The treatment procedure uses 24 treatment doses embedded into child-friendly activities (crafts, book reading, play). Each each consists of a clinician eliciting use of a targeted grammatical form, a child's attempt (correct or incorrect) to use that form, and an immediate clinician repetition of the child's attempt (a recast), correcting any ungrammatical elements as needed. Clinicians must also attempt to gain the child's attention before providing the recast. Treatment sessions are approximately 30 minutes in duration.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
The Average Percent Correct Use of Treated Grammatical Forms in Untreated Contexts
Lasso di tempo: Three sessions conducted on three separate days during the sixth week of treatment.

Clinicians elicit ten uses of the trained grammatical form using toys, activities, and vocabulary with-held from treatment sessions. This is done on each of three days at the end of the treatment period. The percent use calculated as (#correct/10)*100 is calculated over three days at the end of treatment, and these values are averaged for each child. Note that only performance on the hard target is considered in the analysis, even for children previously treated on an easier target. This tests the hypothesis that prior treatment of an easy target speeds learning of a hard target, compared to starting treatment with a hard target. The easy target is not compared to the hard target because, by design, this target to a high level of use, whereas learning levels for the hard target are free to vary.

Three sessions conducted on three separate days during the sixth week of treatment.
Retention of Trained Grammatical Forms
Lasso di tempo: One session, approximately 6 weeks after treatment concludes.

Clinicians elicit ten uses of the trained grammatical form using toys, activities, and vocabulary with-held from treatment sessions and the percent correct use is calculated as (#correct/10)*100.

One session, approximately 6 weeks after treatment concludes.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Overall Treatment Efficacy
Lasso di tempo: Three sessions conducted on three separate days during the sixth week of treatment.

This analysis tests the hypothesis that the treatment in general (collapsed across treatment arms) leads to gains in the use of treated grammatical forms compared with no treatment of grammatical forms. Measures reporting single-participant treatment effect size are typically reported with a Unit of Measure in treatment effect size d. Single-subject treatment effect size d metric reflects gains in morpheme use from baseline levels to the end of treatment, for each individual child. This is calculated for each of the Target and Control morphemes as "Generalization d = ((end treatment percent correct mean - pretreatment percent correct mean)/ (end treatment standard deviation)). Note that the percent correct means are based on the average percent correct use for three sessions pretreatment and during the 6th week of treatment.

Three sessions conducted on three separate days during the sixth week of treatment.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Elena Plante, PhD, University of Arizona

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 febbraio 2022

Completamento primario (Effettivo)

30 ottobre 2024

Completamento dello studio (Effettivo)

30 aprile 2025

Date di iscrizione allo studio

Primo inviato

9 giugno 2023

Primo inviato che soddisfa i criteri di controllo qualità

11 luglio 2023

Primo Inserito (Effettivo)

19 luglio 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

5 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 luglio 2026

Ultimo verificato

1 gennaio 2024

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Altri numeri di identificazione dello studio

  • DLD-Tx1

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Individual participant data, including clinical test scores and outcome measures, are shared in publications and presentations. Other study data is provided by request from the study PI.

Periodo di condivisione IPD

Data is available for sharing after initial publication and for a minimum of 5 years after publication.

Criteri di accesso alla condivisione IPD

Secondary use must be consistent with the intent of the original consent document.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • CODICE_ANALITICO
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .